Is adjuvant immunotherapy indicated for ciliary body melanoma?

Adjuvant Immunotherapy for Ciliary Body Melanoma

Adjuvant immunotherapy is NOT indicated for ciliary body melanoma, as this is a form of uveal (noncutaneous) melanoma, which has fundamentally different biology from cutaneous melanoma and lacks evidence supporting benefit from immune checkpoint inhibitors in the adjuvant setting.

Critical Distinction: Uveal vs. Cutaneous Melanoma

Ciliary body melanoma is a uveal melanoma, not cutaneous melanoma. This distinction is paramount because:

• The ASCO 2023 guidelines explicitly address "noncutaneous melanoma" as a separate clinical question 1, recognizing these are biologically distinct entities
• All major adjuvant immunotherapy trials (CheckMate 238, KEYNOTE-054, COMBI-AD) specifically enrolled only cutaneous melanoma patients and excluded uveal melanomas 1, 2
• The NCCN Guidelines maintain separate guidelines for uveal melanoma versus cutaneous melanoma, underscoring their different treatment paradigms 3

Why Adjuvant Immunotherapy Fails in Uveal Melanoma

Uveal melanomas have:

• Different genetic drivers (primarily BAP1, SF3B1, EIF1AX mutations rather than BRAF/NRAS) 3
• Distinct metastatic patterns (predominantly hematogenous spread to liver, not lymphatic)
• Immunologically "cold" tumor microenvironment with poor response to checkpoint inhibitors
• No randomized trial evidence supporting adjuvant immunotherapy efficacy

Current Standard of Care for Ciliary Body Melanoma

For localized ciliary body melanoma, treatment focuses on:

• Local control: Enucleation, plaque brachytherapy, or proton beam radiation 4, 3
• Surveillance for metastases: Liver imaging given predilection for hepatic metastases
• No adjuvant systemic therapy is standard of care

Role of Immunotherapy: Metastatic Disease Only

Immunotherapy with nivolumab plus ipilimumab may have a role only in the metastatic setting, not as adjuvant therapy:

• Case reports demonstrate complete responses to dual checkpoint inhibition (nivolumab + ipilimumab) in metastatic uveal melanoma involving the ciliary body/choroid 5, 4
• Response rates remain modest compared to cutaneous melanoma
• This is salvage therapy for advanced disease, not adjuvant prevention

Common Pitfall to Avoid

Do not extrapolate cutaneous melanoma adjuvant data to uveal melanoma. Despite both being "melanoma," they are as different as renal cell carcinoma and urothelial carcinoma—both kidney cancers with completely different treatment paradigms. The strong evidence supporting pembrolizumab and nivolumab in resected stage IIB-IV cutaneous melanoma 1 does not apply to ciliary body melanoma.

Clinical Algorithm

For a patient with resected ciliary body melanoma:

1. Confirm pathologic diagnosis of uveal (not cutaneous) melanoma
2. Complete local treatment (surgery or radiation)
3. Initiate surveillance with liver imaging (MRI preferred)
4. Do NOT offer adjuvant immunotherapy
5. Reserve immunotherapy for documented metastatic disease only, preferably in clinical trial

The absence of evidence is not evidence of absence, but in this case, the biological rationale and clinical experience strongly suggest adjuvant immunotherapy would provide no benefit while exposing patients to significant immune-related toxicities (including potential grade 3-4 adverse events in >40% of patients and risk of permanent endocrinopathies) 1, 4.